Nicotine patch therapy in adolescent smokers

Todd A. Smith, Roy F. House, Ivana T Croghan, Thomas R. Gauvin, Robert C. Colligan, Kenneth P. Offord, Leigh C. Gomez-Dahl, Richard D. Hurt

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Objective. To evaluate the safety, tolerance, and efficacy of 24-hour nicotine patch therapy in adolescent smokers who were trying to stop smoking. Design. Nonrandomized, open-label, 6-month clinical trial. Setting. Five public high schools in the Rochester, MN, area. Subjects. Twenty-two adolescent smokers, aged 13 through 17 years, with current smoking rate of 20 or more cigarettes per day (cpd). Intervention. Daily nicotine patch therapy for 8 weeks (22 mg/d for 6 weeks followed by 11 mg/d for 2 weeks). Weekly individual behavioral counseling and group support continued for 8 weeks with follow up visits at 3 and 6 months and a mailed survey at 1 year. Main Outcome Measures. Self-reported smoking abstinence verified by expired air carbon monoxide of 8 ppm or less, nicotine withdrawal symptoms, adverse experiences, and blood cotinine levels. Results. Subjects had a mean ± SD smoking rate of 23.3 ± 5.0 (range, 20 to 35) cpd at study entry and 2.6 ± 1.6 years of smoking; the mean age was 15.9 ± 1.2 (range 13 through 17) years, and 68% were girls. Of the 22 participants, 19 (86%) completed patch therapy, 3 (14%) had biochemically validated smoking cessation at week 8, and 1 continued to be smoke free at 3 and 6 months after patch initiation. There was a significant decrease from baseline in the mean nicotine withdrawal scores for days 4 and 7 of week 1 and the mean for weeks 2 through 8. Skin reactions were the most common adverse event. As the worst skin reactions, 55% had erythema only, 5% had erythema and edema, and 9% had erythema and vesicles, whereas 32% had no skin reactions. Other reported adverse events were headaches (41%), nausea and vomiting (41%), tiredness (41%), dizziness (27%), and arm pain (23%). None of these were considered serious, life threatening, or led to the discontinuation of patch therapy. In adults with comparable smoking rates, we found that the adolescents had lower blood cotinine levels. Those smoking 20 to 25 cpd had cotinine levels of 146 ± 84 (adolescents) vs 260 ± 98 (adults) ng/ml, and those smoking 26 to 35 cpd had levels of 169 ± 73 vs 276 ± 110 ng/ml, respectively. Conclusion. Nicotine patch therapy seems safe in adolescent smokers. Placebo-controlled trials are needed to establish the efficacy of nicotine patch therapy in adolescents.

Original languageEnglish (US)
Pages (from-to)659-667
Number of pages9
JournalPediatrics
Volume98
Issue number4 PART 1
StatePublished - Oct 1996

Fingerprint

Tobacco Use Cessation Products
Smoking
Cotinine
Tobacco Products
Erythema
Therapeutics
Nicotine
Skin
Substance Withdrawal Syndrome
Dizziness
Smoking Cessation
Carbon Monoxide
Smoke
Nausea
Vomiting
Headache
Counseling
Edema
Air
Placebos

Keywords

  • Adolescent smokers
  • Nicotine patch therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Smith, T. A., House, R. F., Croghan, I. T., Gauvin, T. R., Colligan, R. C., Offord, K. P., ... Hurt, R. D. (1996). Nicotine patch therapy in adolescent smokers. Pediatrics, 98(4 PART 1), 659-667.

Nicotine patch therapy in adolescent smokers. / Smith, Todd A.; House, Roy F.; Croghan, Ivana T; Gauvin, Thomas R.; Colligan, Robert C.; Offord, Kenneth P.; Gomez-Dahl, Leigh C.; Hurt, Richard D.

In: Pediatrics, Vol. 98, No. 4 PART 1, 10.1996, p. 659-667.

Research output: Contribution to journalArticle

Smith, TA, House, RF, Croghan, IT, Gauvin, TR, Colligan, RC, Offord, KP, Gomez-Dahl, LC & Hurt, RD 1996, 'Nicotine patch therapy in adolescent smokers', Pediatrics, vol. 98, no. 4 PART 1, pp. 659-667.
Smith TA, House RF, Croghan IT, Gauvin TR, Colligan RC, Offord KP et al. Nicotine patch therapy in adolescent smokers. Pediatrics. 1996 Oct;98(4 PART 1):659-667.
Smith, Todd A. ; House, Roy F. ; Croghan, Ivana T ; Gauvin, Thomas R. ; Colligan, Robert C. ; Offord, Kenneth P. ; Gomez-Dahl, Leigh C. ; Hurt, Richard D. / Nicotine patch therapy in adolescent smokers. In: Pediatrics. 1996 ; Vol. 98, No. 4 PART 1. pp. 659-667.
@article{e2c61aad4e09421aa5556f6d22a5f5eb,
title = "Nicotine patch therapy in adolescent smokers",
abstract = "Objective. To evaluate the safety, tolerance, and efficacy of 24-hour nicotine patch therapy in adolescent smokers who were trying to stop smoking. Design. Nonrandomized, open-label, 6-month clinical trial. Setting. Five public high schools in the Rochester, MN, area. Subjects. Twenty-two adolescent smokers, aged 13 through 17 years, with current smoking rate of 20 or more cigarettes per day (cpd). Intervention. Daily nicotine patch therapy for 8 weeks (22 mg/d for 6 weeks followed by 11 mg/d for 2 weeks). Weekly individual behavioral counseling and group support continued for 8 weeks with follow up visits at 3 and 6 months and a mailed survey at 1 year. Main Outcome Measures. Self-reported smoking abstinence verified by expired air carbon monoxide of 8 ppm or less, nicotine withdrawal symptoms, adverse experiences, and blood cotinine levels. Results. Subjects had a mean ± SD smoking rate of 23.3 ± 5.0 (range, 20 to 35) cpd at study entry and 2.6 ± 1.6 years of smoking; the mean age was 15.9 ± 1.2 (range 13 through 17) years, and 68{\%} were girls. Of the 22 participants, 19 (86{\%}) completed patch therapy, 3 (14{\%}) had biochemically validated smoking cessation at week 8, and 1 continued to be smoke free at 3 and 6 months after patch initiation. There was a significant decrease from baseline in the mean nicotine withdrawal scores for days 4 and 7 of week 1 and the mean for weeks 2 through 8. Skin reactions were the most common adverse event. As the worst skin reactions, 55{\%} had erythema only, 5{\%} had erythema and edema, and 9{\%} had erythema and vesicles, whereas 32{\%} had no skin reactions. Other reported adverse events were headaches (41{\%}), nausea and vomiting (41{\%}), tiredness (41{\%}), dizziness (27{\%}), and arm pain (23{\%}). None of these were considered serious, life threatening, or led to the discontinuation of patch therapy. In adults with comparable smoking rates, we found that the adolescents had lower blood cotinine levels. Those smoking 20 to 25 cpd had cotinine levels of 146 ± 84 (adolescents) vs 260 ± 98 (adults) ng/ml, and those smoking 26 to 35 cpd had levels of 169 ± 73 vs 276 ± 110 ng/ml, respectively. Conclusion. Nicotine patch therapy seems safe in adolescent smokers. Placebo-controlled trials are needed to establish the efficacy of nicotine patch therapy in adolescents.",
keywords = "Adolescent smokers, Nicotine patch therapy",
author = "Smith, {Todd A.} and House, {Roy F.} and Croghan, {Ivana T} and Gauvin, {Thomas R.} and Colligan, {Robert C.} and Offord, {Kenneth P.} and Gomez-Dahl, {Leigh C.} and Hurt, {Richard D.}",
year = "1996",
month = "10",
language = "English (US)",
volume = "98",
pages = "659--667",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4 PART 1",

}

TY - JOUR

T1 - Nicotine patch therapy in adolescent smokers

AU - Smith, Todd A.

AU - House, Roy F.

AU - Croghan, Ivana T

AU - Gauvin, Thomas R.

AU - Colligan, Robert C.

AU - Offord, Kenneth P.

AU - Gomez-Dahl, Leigh C.

AU - Hurt, Richard D.

PY - 1996/10

Y1 - 1996/10

N2 - Objective. To evaluate the safety, tolerance, and efficacy of 24-hour nicotine patch therapy in adolescent smokers who were trying to stop smoking. Design. Nonrandomized, open-label, 6-month clinical trial. Setting. Five public high schools in the Rochester, MN, area. Subjects. Twenty-two adolescent smokers, aged 13 through 17 years, with current smoking rate of 20 or more cigarettes per day (cpd). Intervention. Daily nicotine patch therapy for 8 weeks (22 mg/d for 6 weeks followed by 11 mg/d for 2 weeks). Weekly individual behavioral counseling and group support continued for 8 weeks with follow up visits at 3 and 6 months and a mailed survey at 1 year. Main Outcome Measures. Self-reported smoking abstinence verified by expired air carbon monoxide of 8 ppm or less, nicotine withdrawal symptoms, adverse experiences, and blood cotinine levels. Results. Subjects had a mean ± SD smoking rate of 23.3 ± 5.0 (range, 20 to 35) cpd at study entry and 2.6 ± 1.6 years of smoking; the mean age was 15.9 ± 1.2 (range 13 through 17) years, and 68% were girls. Of the 22 participants, 19 (86%) completed patch therapy, 3 (14%) had biochemically validated smoking cessation at week 8, and 1 continued to be smoke free at 3 and 6 months after patch initiation. There was a significant decrease from baseline in the mean nicotine withdrawal scores for days 4 and 7 of week 1 and the mean for weeks 2 through 8. Skin reactions were the most common adverse event. As the worst skin reactions, 55% had erythema only, 5% had erythema and edema, and 9% had erythema and vesicles, whereas 32% had no skin reactions. Other reported adverse events were headaches (41%), nausea and vomiting (41%), tiredness (41%), dizziness (27%), and arm pain (23%). None of these were considered serious, life threatening, or led to the discontinuation of patch therapy. In adults with comparable smoking rates, we found that the adolescents had lower blood cotinine levels. Those smoking 20 to 25 cpd had cotinine levels of 146 ± 84 (adolescents) vs 260 ± 98 (adults) ng/ml, and those smoking 26 to 35 cpd had levels of 169 ± 73 vs 276 ± 110 ng/ml, respectively. Conclusion. Nicotine patch therapy seems safe in adolescent smokers. Placebo-controlled trials are needed to establish the efficacy of nicotine patch therapy in adolescents.

AB - Objective. To evaluate the safety, tolerance, and efficacy of 24-hour nicotine patch therapy in adolescent smokers who were trying to stop smoking. Design. Nonrandomized, open-label, 6-month clinical trial. Setting. Five public high schools in the Rochester, MN, area. Subjects. Twenty-two adolescent smokers, aged 13 through 17 years, with current smoking rate of 20 or more cigarettes per day (cpd). Intervention. Daily nicotine patch therapy for 8 weeks (22 mg/d for 6 weeks followed by 11 mg/d for 2 weeks). Weekly individual behavioral counseling and group support continued for 8 weeks with follow up visits at 3 and 6 months and a mailed survey at 1 year. Main Outcome Measures. Self-reported smoking abstinence verified by expired air carbon monoxide of 8 ppm or less, nicotine withdrawal symptoms, adverse experiences, and blood cotinine levels. Results. Subjects had a mean ± SD smoking rate of 23.3 ± 5.0 (range, 20 to 35) cpd at study entry and 2.6 ± 1.6 years of smoking; the mean age was 15.9 ± 1.2 (range 13 through 17) years, and 68% were girls. Of the 22 participants, 19 (86%) completed patch therapy, 3 (14%) had biochemically validated smoking cessation at week 8, and 1 continued to be smoke free at 3 and 6 months after patch initiation. There was a significant decrease from baseline in the mean nicotine withdrawal scores for days 4 and 7 of week 1 and the mean for weeks 2 through 8. Skin reactions were the most common adverse event. As the worst skin reactions, 55% had erythema only, 5% had erythema and edema, and 9% had erythema and vesicles, whereas 32% had no skin reactions. Other reported adverse events were headaches (41%), nausea and vomiting (41%), tiredness (41%), dizziness (27%), and arm pain (23%). None of these were considered serious, life threatening, or led to the discontinuation of patch therapy. In adults with comparable smoking rates, we found that the adolescents had lower blood cotinine levels. Those smoking 20 to 25 cpd had cotinine levels of 146 ± 84 (adolescents) vs 260 ± 98 (adults) ng/ml, and those smoking 26 to 35 cpd had levels of 169 ± 73 vs 276 ± 110 ng/ml, respectively. Conclusion. Nicotine patch therapy seems safe in adolescent smokers. Placebo-controlled trials are needed to establish the efficacy of nicotine patch therapy in adolescents.

KW - Adolescent smokers

KW - Nicotine patch therapy

UR - http://www.scopus.com/inward/record.url?scp=0029800963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029800963&partnerID=8YFLogxK

M3 - Article

C2 - 8885942

AN - SCOPUS:0029800963

VL - 98

SP - 659

EP - 667

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4 PART 1

ER -